Mycophenolate in Psoralen-UV-A Desensitization Therapy for Chronic Actinic Dermatitis

Nousari, Hossein C.

doi:10.1001/archderm.135.9.1128

Cited by 31 publications

(17 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…43 MMF has also been used in actinic dermatitis. 45,46 MMF as monotherapy has shown to induce significant improvement within only 6 weeks and eventual complete clearance on a maintenance dose of MMF. 45 MMF may also allow a reduced dosage of prednisone required during psoralen plus ultraviolet A light phototherapy (PUVA) desensitization.…”

Section: Autoimmune Blistering Disordersmentioning

confidence: 99%

“…45 MMF may also allow a reduced dosage of prednisone required during psoralen plus ultraviolet A light phototherapy (PUVA) desensitization. 46 However, this use is controversial, because MMF has been associated with a reported detectable increased risk in lymphoproliferative disease and other malignant neoplasms and may potentiate the photocarcinogenic risk in conjunction with PUVA. 46 Lastly, MMF may be an option for the treatment of dyshidrotic eczema.…”

Section: Autoimmune Blistering Disordersmentioning

confidence: 99%

“…46 However, this use is controversial, because MMF has been associated with a reported detectable increased risk in lymphoproliferative disease and other malignant neoplasms and may potentiate the photocarcinogenic risk in conjunction with PUVA. 46 Lastly, MMF may be an option for the treatment of dyshidrotic eczema. When no underlying trigger mechanism can be detected and only symptomatic therapy can be offered, patients with dyshidrotic eczema are often left with recurrent, relapsing disease.…”

Section: Autoimmune Blistering Disordersmentioning

confidence: 99%

See 2 more Smart Citations

Mycophenolate mofetil in dermatology

Orvis

Wesson

Breza

et al. 2009

Journal of the American Academy of Dermatology

114

106

View full text Add to dashboard Cite

Section: Autoimmune Blistering Disordersmentioning

confidence: 99%

Section: Autoimmune Blistering Disordersmentioning

confidence: 99%

Section: Autoimmune Blistering Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Mycophenolate mofetil in dermatology

Orvis

Wesson

Breza

et al. 2009

Journal of the American Academy of Dermatology

114

106

View full text Add to dashboard Cite

“…Nousari described the use of MMF in PUVA desensitization in two patients as an alternative agent to azathioprine. 44 Treatment of allergic contact dermatitis induced by dinitrofluorobenzene in an experimental guinea pig model suggests that human application of a topical preparation of MPA may be feasible. 45 …”

Section: Eczematous Dermatitismentioning

confidence: 99%

Mycophenolate in dermatology

Liu

Mackool

2003

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Originally used to treat psoriasis nearly three decades ago, mycophenolic acid, reformulated as mycophenolate mofetil (MMF), has been rediscovered by the world of dermatology. As a relatively well-tolerated immunosuppressive used in organ transplant recipients, MMF has recently been reported to show promise for several dermatologic conditions, including psoriasis, pemphigus vulgaris, pyoderma gangrenosum, bullous lichen planus, and even connective tissue diseases such as lupus erythematosus and dermatomyositis. Although not intended to be exhaustive, this review discusses MMF with regard to its basic pharmacology, its side effects, and its reported efficacy in a variety of dermatologic indications. Relevant literature was retrieved by a Medline search combining the terms "mycophenolate" or "mycophenolic acid" and "skin" or "skin disease" or a number of specific conditions ("psoriasis", "dermatitis", "eczema", "pemphigoid", "pemphigus", "vasculitis", "pyoderma gangrenosum", "Crohn's disease", "graft-versus-host disease", "lichen planus"). As MMF has only been recently re-introduced for dermatologic application, the nature of much of the literature is admittedly that of case reports or case series. Nevertheless, the results are sufficiently promising to warrant further larger, control studies.

show abstract

“…Die Therapie der CAD mit Mycophenolatmofetil in Kombination mit systemischer PUVA-Therapie stellt eine sinnvolle Therapieoption bei schweren Formen der CAD dar [3,4,5]. Für Mycophenolatmofetil wird vom Hersteller ein erhöhtes Risiko für nichtmelanozytäre Hauttumore von 3,6% angegeben.…”

Section: Introductionunclassified

Chronisch aktinische Dermatitis

et al. 2010

View full text Add to dashboard Cite

A 66-year-old man was diagnosed with psoriasis in 2001 and treated accordingly; in 2007, the diagnosis was switched to atopic dermatitis and the therapy modified. Initially he improved with fumarates and methotrexate, but then experienced recurrent exacerbations with erythroderma and severe superinfection requiring hospitalization. Based on the modified clinical picture with striking accentuation on the head and back of the hands, we diagnosed chronic actinic dermatitis. In September 2008 immunosuppressive therapy with mycophenolate mophetil (2×500 mg/d) was started. Since the response was modest, photo-hardening with systemic photochemotherapy (PUVA) was added, producing close to complete recovery within 6 months.

show abstract

Mycophenolate in Psoralen-UV-A Desensitization Therapy for Chronic Actinic Dermatitis

Cited by 31 publications

References 3 publications

Mycophenolate mofetil in dermatology

Mycophenolate mofetil in dermatology

Mycophenolate in dermatology

Chronisch aktinische Dermatitis

Contact Info

Product

Resources

About